Lesaffre Human Care Launches Probiotic Yeast to Target IBS

05 May 2015 --- Lesaffre Human Care has received backing from the scientific community for its new patented ingredient for digestive health. The product, formerly known as Lynside Pro GI+ and now rebranded as ibSium, has been designed to specifically target Irritable Bowel symptoms. The new brand identity will be revealed at Vitafoods Europe, which takes place May 5 – 7 in Geneva.

This specific strain of Saccharomyces cerevisiae, selected by Lesaffre among thousands of proprietary strains and registered with the French National Collection of Microorganism Cultures as CNCM I¬3856, demonstrated a significant effect in improving abdominal pain and discomfort in individuals with Irritable Bowel Syndrome after four weeks of administration in 63% of subjects receiving the strain Saccharomyces cerevisiae CNCM I-3856 against 47% in the placebo group (p=0.04). The study also showed no adverse side effects or habituation that can be caused by prescription drugs often used to treat this condition.

This patented strain of Saccharomyces cerevisiae is therefore a real breakthrough in IBS-related symptoms management; offering thousands of people afflicted by this gastrointestinal disorder, the perfect all-natural partner for long term use.

In addition to preclinical and clinical evidence highlighting Saccharomyces cerevisiae CNCM I-3856’s efficacy in relieving IBS symptoms, the probiotic yeast was also acclaimed by end-consumers who gave a thumbs up to this side effects-free alternative solution to manage their symptoms, through a large consumer study performed in collaboration with prescribing physicians.

The recent publication of a first clinical study on this unique probiotic yeast in the journal ‘Digestive and Liver Disease’ represents for Lesaffre Human Care an important backing from the scientific community. Another article, about a second clinical study, is also currently under consideration for publication.

Irritable Bowel Syndrome is one of the most prevalent gastrointestinal disorders in the world affecting up to 20% of adults in certain areas and representing one of the leading causes of work absenteeism. With abdominal pain and/or discomfort and bloating as the main symptoms, IBS substantially alters patient’s quality of life, which is why thousands of people unsatisfied with their current treatment are now looking for a long-term alternative solution to effectively manage their symptoms.

With ibSium, an all-natural treatment option is now available without the side effects or habituation that can be caused by prescription drugs often used for this condition.